Arcturus Therapeutics Holdings Inc.
Financials
Valuation Metrics
Arcturus Therapeutics Holdings Inc.'s Market Cap is $456M. At end of 2025 it was $168M. Ranked #2810 of 3,121 in US market (top 90%), #1234 of 1,463 on NASDAQ (top 84%), #226 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 85%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $456M | US#2,810/3,121 Sec#226/266 |
| Revenue | $24M | US#2,813/3,121 Sec#163/266 |
| Net Income | $-93M | US—/3,121 Sec—/266 |
| Total Assets | $224M | US#2,978/3,121 Sec#241/266 |
| Net Assets | $172M | US#2,719/3,121 Sec#199/266 |
| Employees | 109 | US#2,611/3,121 Sec#172/266 |
| Value | ||
| P/B | 2.65x | US#1,668/3,121 Sec#80/266 |
| P/S | 19.14x | US#2,847/3,121 Sec#144/266 |
| FCF Yield | -16.03% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -54.29% | US#2,698/3,121 Sec#161/266 |
| ROA | -41.58% | US#2,954/3,121 Sec#193/266 |
| Op. Margin | -433.36% | US#2,803/3,121 Sec#153/266 |
| Revenue Growth | -79.07% | US#2,763/3,121 Sec#177/266 |
| Financial Health | ||
| Debt Ratio | 30.56% | US#346/3,121 Sec#107/266 |
| Total Debt | $23M | US#2,734/3,121 Sec#184/266 |
| FCF | $-73M | US#2,581/3,121 Sec#128/266 |
| Cash | $191M | US#1,769/3,121 Sec#112/266 |
| Current Ratio | 5.88x | US#403/3,121 Sec#127/266 |
| Performance | ||
| 1Y Return | -18.30% | US#2,010/3,121 Sec#194/266 |
| 1M Return | 55.93% | US#5/3,121 Sec#3/266 |
| From 52W High | -33.68% | US#2,062/3,121 Sec#161/266 |
| 1Y MDD | -76.12% | US#3,031/3,121 Sec#248/266 |
| Trading | ||
| Volume | 753,859 shares | US#1,185/3,121 Sec#119/266 |
| Trading Value | $12M | US#1,825/3,121 Sec#142/266 |
| Per Share | ||
| EPS | $-3.28 | US—/3,121 Sec—/266 |
| BPS | $6.04 | US#2,188/3,121 Sec#110/266 |
Company Info
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.